On the other hand, even though the mechanism of TSH is also unclear, thyroid dysfunction is a prevalent irAE in NSCLC patients treated with the anti-PD1 antibody nivolumab (37) and thus is not surprising to perform well in this study. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.